Deltex Medical Group

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Deltex Medical Group, Annual general meeting, Pakistan Society of Neuro-Oncology, Progression-free survival, University, HSCT, ASH, Cohort, Glioblastoma, TTP, IND, GBM, Leukemia, Patient, Research and development, Abstract, Cleveland Clinic, PFS, Research, Immunotherapy, CRS, IPSC, ORR, CD33, Ovarian cancer, Cancer, Development, CML, Survival, Bone marrow, SITC, Arms, AML, Gamma delta T cell, Society, SNO, CD123, Poster, KOL, University of Chicago, DRI, Pharmaceutical industry, Medical imaging

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023
Pakistan Society of Neuro-Oncology, Survival, GBM, Temozolomide, NKG2D, DRI, Immune reconstitution inflammatory syndrome, SNO, American Society of Clinical Oncology, Glioblastoma, Society, SITC, Immunotherapy, Immune system, Annual general meeting, Deltex Medical Group, TMZ, Cancer, Patient, Abstract, ASCO, Vaccine, Medical imaging

A treated patient, with paired tissue biopsies, demonstrated infiltration of gamma-delta T cells 148 days following a single administration in Cohort 1.

Key Points: 
  • A treated patient, with paired tissue biopsies, demonstrated infiltration of gamma-delta T cells 148 days following a single administration in Cohort 1.
  • Updated patient, survival and enrollment data from the ongoing INB-200 study to be presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023 from 7:30 PM – 9:30 PM PT (Abstract Number: CTIM-42).
  • In June 2023, IN8bio presented positive data from the Phase 1 study of INB-200 in an oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
  • The Company will present updated patient, survival and enrollment data from the study at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 15-19, 2023.

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

Retrieved on: 
Tuesday, September 19, 2023
Genetic engineering, GBM, Cancer, Hope, NK, Cell, IP, HSCT, Pharmacotherapy, Food and Drug Administration Amendments Act of 2007, Leukemia, Patient, DRI, CPI-0610, Growth, FDA, Food, Deltex Medical Group, Vaccine, Pharmaceutical industry

IN8bio now holds 19 total granted U.S. and international patents, and numerous pending patent applications.

Key Points: 
  • IN8bio now holds 19 total granted U.S. and international patents, and numerous pending patent applications.
  • NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced significant updates to its foundational IP portfolio.
  • The company was recently granted patents around the world that cover use of the combination of its proprietary DeltEx DRI platform with CAR-T and CPI’s.
  • IN8bio boasts a strong IP portfolio of granted patents encompassing the DRI, CAR-T and HSCT families, with multiple additional applications pending globally to further expand its patent portfolio and IP position.

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
GMP, Abstract, Society, ASH, GBM, D&O, Progression-free survival, Survival, Cancer, SITC, SNO, Immunotherapy, Pakistan Society of Neuro-Oncology, Research, Brain, PFS, Glioblastoma, ASCO, Research and development, Development, Patient, DRI, TTP, Annual general meeting, Society for Immunotherapy of Cancer, R, Ovarian cancer, Safety, ORR, Deltex Medical Group, Pharmaceutical industry, Vaccine, Airline

INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023.

Key Points: 
  • INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023.
  • In addition, the Company provided an overview of recent corporate developments through August 2023.
  • The Company will be hosting an R&D Day on Thursday, October 12, 2023 in New York City, with details to follow.
  • Cash: As of June 30, 2023, the Company had cash of $17.0 million, compared to $10.9 million as of March 31, 2023.

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

Retrieved on: 
Monday, December 12, 2022
HSCT, Lymphatic system, Blood, Security (finance), Fatigue, Webcast, Principal investigator, Exposition, ASH, Infrared spectroscopy correlation table, Vomiting, CMV, AML, Hematopoietic stem cell transplantation, Cohort, COVID-19, Glioblastoma, Hematology-Oncology and Stem Cell Transplantation Research Center, Graft-versus-host disease, University, Clinical trial, Safety, CRS, Constipation, Society, KUCC, IPSC, Deltex Medical Group, Disease, Immune system, Medical director, Patient, Cytomegalovirus, Leukemia, Cytokine release syndrome, AES, Poster, Magnesium, CR, Acute myeloid leukemia, Risk, Event, Pharmaceutical industry, Medical imaging

As of December 9, 2022, four patients have received the first dose level (DL) of INB-100 (1 x 106 cells/kg) and remain on study and in remission.

Key Points: 
  • As of December 9, 2022, four patients have received the first dose level (DL) of INB-100 (1 x 106 cells/kg) and remain on study and in remission.
  • Steroid-responsive cutaneous acute Grade 1/2 graft-versus-host disease (GvHD) has been observed in all patients, with one patient experiencing Grade 2 intestinal GvHD.
  • Two patients have been enrolled and dosed in Cohort 2, evaluating INB-100 at a dose level of 3 x 106 cells/kg.
  • IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.

IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Retrieved on: 
Thursday, December 8, 2022
CMC, Clinical trial, Leukemia, Progression-free survival, Security (finance), Food, FDA, Safety, Webcast, Cancer, GBM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASH, TTP, IPSC, ORR, Hematopoietic stem cell transplantation, Deltex Medical Group, Society, IND, DRI, Arm, Risk, COVID-19, Glioblastoma, Patient, PFS, Event, Pharmaceutical industry, Medical imaging

The study will assess the safety, efficacy and tolerability of genetically modified DeltEx drug-resistant immunotherapy (DRI) cells at leading medical centers across the United States.

Key Points: 
  • The study will assess the safety, efficacy and tolerability of genetically modified DeltEx drug-resistant immunotherapy (DRI) cells at leading medical centers across the United States.
  • “Obtaining clearance to begin the INB-400 Phase 2 clinical trial is an important milestone for IN8bio as it is our first company-sponsored IND.
  • “The clinical program is designed to eventually assess DeltEx DRI with both autologous and allogeneic approaches in both the front-line and relapsed setting.
  • ET to review recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being presented at ASH.

IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, University of Louisville School of Medicine, Infrared spectroscopy correlation table, IND, Lymphoma, Forward-looking statement, Business development, Patent, U.S. Securities and Exchange Commission, Haematopoietic system, IPSC, Partnership, Nasdaq, Research, CR, Chicago (franchise), Risk, Society, Population, COVID-19, Glioblastoma, R, SEC, Hematopoietic stem cell transplantation, Potency (pharmacology), Dunbar, Company, Cancer, AML, Coronavirus Scientific Advisory Board (Turkey), Clinical trial, University, NK, Patient, GMP, NEW, CEO, Security (finance), Deltex Medical Group, Industry, Insurance, ASH, Leukemia, FDA, Pharmaceutical industry, Vaccine, Medicine

Strengthened the balance sheet through an equity offering raising net proceeds of $9.8 million; cash position of $27.6 million as of September 30, 2022.

Key Points: 
  • Strengthened the balance sheet through an equity offering raising net proceeds of $9.8 million; cash position of $27.6 million as of September 30, 2022.
  • NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results, corporate developments, and operational highlights for the third quarter ended September 30, 2022.
  • We achieved several important corporate goals during the third quarter that had been the focus of our teams energy for much of 2022.
  • IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors.

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
NEW, Private Securities Litigation Reform Act, Progression-free survival, Fatigue, Infrared spectroscopy correlation table, Cohort, Society, Glioblastoma, Hematopoietic stem cell transplantation, GLOBE, Deltex Medical Group, HSCT, Population, Cytokine release syndrome, Safety, CMV, AES, IPSC, ASH, CRS, KUCC, COVID-19, Magnesium, Nasdaq, Graft-versus-host disease, Investigator's brochure, CR, U.S. Securities and Exchange Commission, Clinical trial, Forward-looking statement, Risk, Vomiting, Constipation, Cytomegalovirus, University, Security (finance), Immune system, AML, SEC, Leukemia, Patient, Pharmaceutical industry, Vaccine, Medical imaging, Cyclophosphamide

These early signs of long-term durability and progression-free survival demonstrate the potential of INB-100 as a new treatment option in this patient population.

Key Points: 
  • These early signs of long-term durability and progression-free survival demonstrate the potential of INB-100 as a new treatment option in this patient population.
  • These data suggest that treatment with a one-time allogeneic gamma-delta T cell therapy has the potential to disrupt the treatment paradigm for AML.
  • We look forward to sharing updated data at ASH and additional data at future peer-reviewed conferences.
  • The abstract highlights data from Cohort 1 of the ongoing Phase 1 clinical trial of INB-100 in patients with high-risk AML undergoing HSCT.

IN8bio to Present at November Investor Conferences

Retrieved on: 
Tuesday, November 1, 2022
Hematopoietic stem cell transplantation, Patient, Genotype-first approach, GLOBE, Population, CEO, Cancer, Nasdaq, IPSC, Glioblastoma, Deltex Medical Group, Therapy, Leukemia, Medical imaging

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor conferences in November.

Key Points: 
  • NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor conferences in November.
  • ET
    IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors.
  • IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
  • For more information about IN8bio and its programs, please visit www.IN8bio.com .

IN8bio to Present at Cantor Oncology & HemOnc Conference

Retrieved on: 
Tuesday, September 27, 2022
Leukemia, Hematopoietic stem cell transplantation, Conference, GLOBE, IPSC, Population, Deltex Medical Group, Nasdaq, Glioblastoma, Patient, Medical imaging

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bios Chief Executive Officer, will be a speaker on the Cell Therapy in Solid Tumors panel at the Cantor Oncology & HemOnc Conference.

Key Points: 
  • NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bios Chief Executive Officer, will be a speaker on the Cell Therapy in Solid Tumors panel at the Cantor Oncology & HemOnc Conference.
  • IN8bio is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gamma-delta T cell product candidates for solid and liquid tumors.
  • IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
  • For more information about IN8bio and its programs, please visit www.IN8bio.com .